Clinical Implications of Monitoring ESR1 Mutations by Circulating Tumor DNA in Estrogen Receptor Positive Metastatic Breast Cancer: A Pilot Study

BACKGROUND: ESR1 mutations are frequently detected in ER+ MBC, and have been reported to be associated with endocrine therapy resistance. However, there are little researches to validate whether dynamic monitoring of ESR1 mutations could serve as a predictive plasma biomarker of acquired resistance...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Xuelu, Lu, Jiawei, Zhang, Lanxin, Luo, Yaoting, Zhao, Zuowei, Li, Man
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Neoplasia Press 2019
Materias:
Original article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6931202/
https://www.ncbi.nlm.nih.gov/pubmed/31877464
http://dx.doi.org/10.1016/j.tranon.2019.11.007

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6931202/
https://www.ncbi.nlm.nih.gov/pubmed/31877464
http://dx.doi.org/10.1016/j.tranon.2019.11.007

Ejemplares similares